Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening – Webinar Presentation – Video

By LizaAVILA



14-12-2011 20:22 Human tissue cells derived from induced pluripotent stem (iPS) cells recapitulate many of the characteristics and functionality expected of in vivo cell types. iCell® Cardiomyocytes are derived from human IPS cells and are currently being used in both drug discovery and basic research in Industrial and Academic settings. Dr. Eric Chiao of Hoffmann-La Roche Inc. (Roche) will lead this presentation and provide data showing the characterization and utility of iCell Cardiomyocytes, how they are being used in drug development, and how they are increasing our understanding of basic human cardiomyocyte cellular biology.

More here:
Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation - Video

Related Post


categoriaCardiac Stem Cells commentoComments Off on Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening – Webinar Presentation – Video | dataFebruary 7th, 2012

About...

This author published 890 posts in this site.
Just for fun

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024